Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
出版年份 2020 全文链接
标题
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 9, Pages 3157
出版商
MDPI AG
发表日期
2020-04-30
DOI
10.3390/ijms21093157
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma
- (2019) Ghassan K. Abou-Alfa et al. JAMA Oncology
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- (2019) Yukio Hosomi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study
- (2018) Xinan Sheng et al. EUROPEAN JOURNAL OF CANCER
- Tumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones
- (2018) Lina Al-Akra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
- (2018) Laura N. Eadie et al. PLoS One
- Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib
- (2018) Rocio I.R. Macias et al. Oncotarget
- Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
- (2018) Chun-Yan Lan et al. LANCET ONCOLOGY
- P-glycoprotein and Breast Cancer Resistance Protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
- (2018) Wenlong Li et al. PHARMACOLOGICAL RESEARCH
- ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
- (2018) Aleksandra Adamska et al. WORLD JOURNAL OF GASTROENTEROLOGY
- ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
- (2018) Hongbo Zhao et al. Frontiers in Pharmacology
- Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells
- (2017) Annapina Russo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle
- (2017) Zilan Zhou et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells
- (2017) Yan Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer
- (2017) Bernhard Englinger et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2
- (2017) Hiroshi Arakawa et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma
- (2017) Lei Wang et al. MEDICINE
- The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
- (2017) Hui Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
- (2017) Stéphanie van Hoppe et al. PHARMACOLOGICAL RESEARCH
- Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
- (2017) Guan-Nan Zhang et al. PHARMACOLOGICAL RESEARCH
- Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
- (2017) Jun Li et al. Oncotarget
- Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
- (2017) Branka Radic-Sarikas et al. Scientific Reports
- “Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy
- (2016) Jessica A. Kemp et al. ADVANCED DRUG DELIVERY REVIEWS
- TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux
- (2016) Ronilda D'Cunha et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy
- (2016) Caroline Gay et al. HEMATOLOGICAL ONCOLOGY
- Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
- (2016) Joel W Neal et al. LANCET ONCOLOGY
- Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo
- (2016) Z. Chen et al. MOLECULAR CANCER THERAPEUTICS
- MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
- (2016) Tetsu Tomonari et al. Oncotarget
- Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression
- (2016) Bernhard Englinger et al. Oncotarget
- Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) E. Massarelli et al. ANNALS OF ONCOLOGY
- The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial
- (2015) Hamed Emami et al. ATHEROSCLEROSIS
- Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen
- (2015) Leanna Cheung et al. BIOCHEMICAL PHARMACOLOGY
- Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia
- (2015) Kenneth K.W. To et al. BIOCHEMICAL PHARMACOLOGY
- Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
- (2015) D.-Y. Kim et al. BLOOD
- Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death
- (2015) E. I. Zimmerman et al. CANCER RESEARCH
- Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)
- (2015) Patric J. Jansson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
- (2015) R Paul Symonds et al. LANCET ONCOLOGY
- SLC transporters as therapeutic targets: emerging opportunities
- (2015) Lawrence Lin et al. NATURE REVIEWS DRUG DISCOVERY
- Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib
- (2015) James N. Wilson et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition
- (2015) P Nowak-Sliwinska et al. Cell Death & Disease
- Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
- (2015) Kristy J. Gotink et al. CELLULAR ONCOLOGY
- Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo
- (2015) Jing Hu et al. Oncotarget
- Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
- (2015) De-Shen Wang et al. Oncotarget
- Combined MTOR and autophagy inhibition
- (2014) Reshma Rangwala et al. Autophagy
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
- (2014) Myrna R Rosenfeld et al. Autophagy
- Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1
- (2014) Yi-Jun Wang et al. BIOCHEMICAL PHARMACOLOGY
- Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
- (2014) Kamlesh Sodani et al. BIOCHEMICAL PHARMACOLOGY
- Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
- (2014) S Hu et al. BRITISH JOURNAL OF CANCER
- In vitro,in vivoandex vivocharacterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1
- (2014) Hui Zhang et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors
- (2014) Clinton F. Stewart et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance
- (2014) Hui Zhang et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
- (2014) RISHIL J. KATHAWALA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2014) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein
- (2014) Qing-feng Xiang et al. LIVER INTERNATIONAL
- Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10-Mediated Paclitaxel Resistance: A Preclinical Study
- (2014) R. J. Kathawala et al. MOLECULAR CANCER THERAPEUTICS
- Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering
- (2014) Dan Fu et al. Nature Chemistry
- Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells
- (2014) YUE-LI SUN et al. ONCOLOGY REPORTS
- Correction: Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)
- (2014) Tong Shen et al. PLoS One
- Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells
- (2014) Federico Colombo et al. PLoS One
- Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
- (2013) L W-C Chow et al. BRITISH JOURNAL OF CANCER
- Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance
- (2013) Timo Hupfeld et al. BRITISH JOURNAL OF HAEMATOLOGY
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration
- (2013) Tetsuo Yamagishi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)
- (2013) Bulent Cetin et al. JOURNAL OF CHEMOTHERAPY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance
- (2013) A.-M. Ellegaard et al. MOLECULAR CANCER THERAPEUTICS
- Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
- (2013) Zu-Yao Yang et al. PLoS One
- Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
- (2012) J H Yi et al. BRITISH JOURNAL OF CANCER
- Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
- (2012) Amit K. Tiwari et al. CANCER LETTERS
- Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistancein vitroandin vivo
- (2012) Ke-Jun Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis
- (2012) Hee Kyung Ahn et al. LUNG CANCER
- The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
- (2012) R. Sen et al. MOLECULAR CANCER THERAPEUTICS
- Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency
- (2012) Q. McAfee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib
- (2011) Yoshihiko Shibayama et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
- (2011) Wei-Chien Huang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
- (2011) T. Minematsu et al. MOLECULAR CANCER THERAPEUTICS
- The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
- (2011) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells
- (2011) Yun-Ju Chen et al. PLoS One
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
- (2010) Y.-j. Mi et al. CANCER RESEARCH
- Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
- (2010) C. J. Morrow et al. CANCER RESEARCH
- Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation
- (2010) M. A. Elmeliegy et al. CLINICAL CANCER RESEARCH
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
- (2010) H. Hirte et al. GYNECOLOGIC ONCOLOGY
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity
- (2010) J R Engler et al. LEUKEMIA
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A high content screening assay for identifying lysosomotropic compounds
- (2010) Sashi Nadanaciva et al. TOXICOLOGY IN VITRO
- Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier
- (2010) David S. Miller TRENDS IN PHARMACOLOGICAL SCIENCES
- Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
- (2009) Ye-Hong Kuang et al. BIOCHEMICAL PHARMACOLOGY
- Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin
- (2009) Giovanni Luca Beretta et al. BIOCHEMICAL PHARMACOLOGY
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function
- (2009) Li-yang Tao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters
- (2009) S. Hu et al. CLINICAL CANCER RESEARCH
- ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug
- (2009) B. Chapuy et al. HAEMATOLOGICA
- Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
- (2009) D K Hiwase et al. LEUKEMIA
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function
- (2009) Li-sheng Zheng et al. PLoS One
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Interaction of Imatinib with Human Organic Ion Carriers
- (2008) S. Hu et al. CLINICAL CANCER RESEARCH
- Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
- (2008) S. Shukla et al. DRUG METABOLISM AND DISPOSITION
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
- (2008) C. Louvet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started